arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

PUMA BIOTECHNOLOGY, INC.

PBYI
$9.29 ▼ -0.55 (-5.59%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
71 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
80
Health
Good
Bullish
auto_awesome

Analytical Summary

PUMA BIOTECHNOLOGY, INC. shows strong fundamentals with top-quartile Return on Common Equity (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $473.2M
Dividend Yield
Revenue Growth 7.8%
Op. Margin 13.4%
ROIC 4.3%
FCF / Share $0.03
Trailing P/E 58.1x
Price / Book 3.4x
FCF Yield 0.3%
Debt / Equity 0.00
info Valuation on last close. End-of-day price, Sep 23, 2026.

71-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$56.50M
↑ +7.8%
Net Income Profit after all expenses
$8.19M
↑ +39.9%
Operating Margin Operating profit as % of sales
13.4%
↑ +257.2% 69th
FCF / Share Free cash flow per share
$0.03
↓ -89.5%
Long-Term Debt Long-term obligations
$0.00
↓ -100.0%
trending_up

Bullish Indicators

  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability
74
Returns
90
Financial Health
76
Cash Quality
77

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 16 years · 71 quarters